Osteonecrosis of the jaw (ONJ) is a reported complication of bisphosphonate use. The incidence ranges between 6 and 13% and seems to be higher in people treated with zoledronic acid (ZA) than with pamidronate. We retrospectively evaluated the incidences of ONJ and skeletal-related events (SRE) in 106 patients with multiple myeloma divided in two groups according to the schedule of administration of bisphosphonates: 51 received monthly administrations until tolerated (group A, standard schedule), 55 were treated monthly during the first year and then every 3 months (group B, reduced schedule). The incidence of SRE was similar (15.1 per 100 person years in group A and 17.7 in group B). ONJ occurred in seven patients, six in group A and one in group B (P ¼ 0.049). The risk of ONJ was eight-fold lower with the reduced schedule than with the standard schedule. The only significant risk factor for ONJ was the type of bisphosphonate (P ¼ 0.006). The incidence of ONJ was significantly higher with ZA than with pamidronate þ ZA (9.1 vs 1.6 per 100 person-years). No ONJ was observed in patients treated only with pamidronate. A reduced schedule of ZA may be safer than the standard schedule while maintaining anti-resorptive efficacy.
Introduction
Bone disease is the major cause of morbidity and mortality in patients with multiple myeloma (MM), leading to severe pain, pathological fractures, spinal cord compression and hypercalcemia. 1 Both plasma cells and stromal cells produce factors that enhance osteoclast formation and activity, resulting in an unbalanced bone turnover, with increased bone resorption not matched by adequate bone formation. 2 Bisphosphonates are potent inhibitors of osteoclastic activity 3 and play a key role in the management of cancer-related bone disease. Monthly infusions of pamidronate disodium, a second-generation bisphosphonate, given in addition to anti-myeloma therapy, significantly reduced skeletal complications in randomized, placebo-controlled trials. 4, 5 Zoledronic acid (ZA), a newgeneration bisphosphonate, was demonstrated to have a higher potency than pamidronate in preclinical studies. 6 This potency was confirmed in clinical trials, in which ZA was more effective than pamidronate in the treatment of hypercalcemia of malignancy. 7 Furthermore, ZA, administered every 3-4 weeks for 25 months was at least as effective as pamidronate in reducing the risk of skeletal complications in MM patients, while having a similar safety profile and the advantage of a shorter infusion time. 8 Adverse events related to bisphosphonates are uncommon and include bone pain, nausea, fatigue and pyrexia. 8 More recently, avascular osteonecrosis of the jaw (ONJ) has been increasingly reported in patients treated with bisphosphonates. [9] [10] [11] [12] This complication usually presents as a non-healing lesion in the oral cavity strictly related to dental procedures. The etiology is still unclear: microcirculatory alterations, a hypercoagulable state or osteomyelitis have been postulated as possible causes. The length of exposure to bisphosphonates and a history of dental procedures are commonly recognized as the main risk factors for ONJ, raising some concerns about the safety of longterm treatment with bisphosphonates. Given that ZA has some proven advantages over pamidronate, it is conceivable that a different schedule of administration of bisphosphonates could lower the incidence of ONJ, while maintaining the same therapeutic efficacy.
The purpose of this retrospective single-centre study was to compare the incidences of ONJ and skeletal-related events (SRE) in a cohort of MM patients treated with bisphosphonates administered either with a standard schedule (monthly infusions until tolerated) or with an alternative schedule, with the bisphosphonate administered monthly during the first year and then every 3 months.
Patients and methods
In this retrospective single-centre study we included MM patients treated with pamidronate or ZA for at least 1 year. Pamidronate was administered at the dose of 90 mg as a 2-h infusion and ZA at the dose of 4 mg in a 20-minute infusion. All patients received a bisphosphonate every 4 weeks for the first year and then the drugs were administered according to two different schedules. One group of patients proceeded with monthly administrations (group A) while, in the other group, the frequency of bisphosphonate administration was reduced to every 3 months (group B). According to the 2002 ASCO guidelines 13 (Berenson 2002) , bisphosphonates were continued until the patients developed significant side effects related to the drug or until the benefits were considered to be less than the inconvenience of treatment. For patients who developed ONJ, the bisphosphonate was discontinued permanently when possible; otherwise, after a period of suspension, it was resumed at a reduced schedule. The median duration of bisphosphonate treatment was 31 months (interquartile range, IQR 21-46). Patients had received a median of 20 infusions over their entire treatment history (IQR 14-30).
The clinical data recorded for all the patients were age, sex, extent of bone disease at the time of starting bisphosphonates (limited or diffuse), type of bisphosphonate administered (pamidronate or ZA alone or in sequence), number of infusions, duration of treatment, schedule of bisphosphonate administration from the second year (standard or reduced), status of disease (responsive or refractory) and bone disease (stable or in progression) after the first year of therapy with bisphosphonates, history of therapy with thalidomide, incidence of SRE, time to the first SRE, type of SRE, occurrence of ONJ, and time from the start of bisphosphonate therapy to ONJ. Radiographic skeletal survey was used to evaluate bone disease at the start of bisphosphonates treatment and during the follow-up. Magnetic resonance imaging was performed in selected cases.
A SRE was defined as the occurrence of one of the following conditions: a pathological fracture, surgery to treat or prevent pathological fractures, radiation to bone, spinal cord compression associated with vertebral compression fractures or hypercalcemia412 mg/dl. The diagnosis of ONJ was suspected in the presence of signs and symptoms such as pain, soft-tissue swelling or exposed bone. All patients with a suspicion of ONJ were referred to a maxillofacial surgeon and underwent a computed tomography scan of the jaw. The diagnosis was mainly clinical, but a biopsy of the lesion was performed in four patients to exclude a myeloma localization.
Design of the study
This is an observational longitudinal study primarily aimed at comparing the role of two treatment schedules (standard and reduced) on the occurrence of both ONJ and SRE over a median follow-up of 23.5 months (IQR 14.9-37.8 months). The role of the type of bisphosphonate therapy and of other patients' characteristics in determining ONJ was analyzed as a secondary end point.
Statistical analysis
Data are summarized as medians and 25-75th percentiles (IQR) for continuous variables and as counts and percentages for categorical variables. Patients' characteristics at the start of the treatment with bisphosphonates were compared by means of the Mann-Whitney U-test and Fisher's exact test. The median follow-up and its IQR were computed according to the inverse Kaplan-Meier method. The Kruskall-Wallis test was used to compare duration and intensity of exposure of the three-drug combinations. The Bonferroni correction was applied for posthoc comparisons.
The prognostic role of the schedule on the occurrence of ONJ and of SRE over time was assessed by Cox regression models.
The hazard ratio (HR) and its 95% confidence interval (95% CI) were computed. Incidence rates per 100 person-years and their 95% CI were also reported for each end point. The proportional hazard assumption was tested based on Schoenfeld residuals. The follow-up started 1 year after starting treatment with bisphosphonates and ended at the occurrence of the end point under consideration (ONJ or SRE) or at censoring. Observations were censored at the end of the study or at the occurrence of the other end point (SRE or ONJ, respectively). A propensity score for choosing either one of the two schedules was built by means of logistic regression analysis. The following variables were included in the model: age, gender, extent of bone disease (limited/diffuse), type of bisphosphonate (pamidronate only/ZA7pamidronate) and bone disease status at the end of year 1 (stable/progression). The tertiles of its distribution were used for adjusting the prognostic effect of the schedules on the two end points. Other predictors of ONJ were also evaluated by means of Cox regression or the log-rank test. The linearity assumption for continuous predictors was assessed by means of the likelihood ratio test. Stata 9.2 software (Stata Corp, College Station, TX, USA) was used for all computations. A two-sided Po0.05 was considered statistically significant.
Results

Baseline characteristics
Fifty-one patients received standard monthly treatment with bisphosphonates until tolerated (group A), whereas 55 patients (Group B) were treated with the reduced schedule. The patients' characteristics at the end of year 1 (the start of the study) are reported in Table 1 . As shown, the two groups were comparable for age, sex, extent of bone disease, disease status, type of bisphosphonate and concomitant administration of thalidomide.
Treatment schedule and SRE
Twenty-eight SRE were observed over a total follow-up of 2027 person-months, with an incidence rate of 16.6. SRE per 100 person-years (95% CI 11.4-24.0); 11 SRE were observed in the standard schedule group, after a median study time of 20.6 months (IQR 7.9-36.1), and 17 in the reduced schedule group, after a median study time of 12.5 months (IQR 8.1-26.5). The corresponding incidences were similar and were computed to be 15.1 (95% CI 8.4-27.3) and 17.7 (95% CI 11.0-28.4) SRE per 100 person-years, respectively. No significant difference was found between the two groups ( Figure 1 ): at Cox regression, the HR for SRE (adjusted for the tertiles of the propensity score) in patients receiving the reduced schedule with respect to the Reduced risk of ONJ with a different schedule of zoledronic acid A Corso et al standard schedule was estimated to be 1.27 (95% CI 0.58-2.81; P ¼ 0.547).
Treatment schedule and ONJ
Seven cases of ONJ were observed over a total follow-up of 2583 person-months, with an incidence rate of 3.2. cases per 100 person-years (95% CI 1.5-6.2). Six cases of ONJ occurred in the standard schedule group, after a median study time of 10.8 months (IQR 7.3-36.5), and one in the reduced schedule group, 25.8 months after the start of the study. The corresponding incidences were computed to be 6.7 (95% CI 3.0-14.8) and 0.8 (95% CI 0.1-5.7) cases of ONJ per 100 person-years, respectively. Adjusted Cox regression analysis showed a significant difference in ONJ-free survival, with an adjusted HR of 0.12 (95% CI 0.01-99.4; P ¼ 0.049) in the group receiving the reduced schedule with respect to the group receiving the standard schedule ( Figure 2 ). As shown in the figure, more than half of the cases of ONJ (4/7) occurred during the first year of the study (second year of treatment).
Type of bisphosphonate and other predictors of ONJ (secondary end points)
The potential prognostic role of a series of demographic and clinical risk factors on the occurrence of ONJ over follow-up is summarized in Table 2 . The only significant difference in the rate of ONJ was observed for the type of bisphosphonate (P ¼ 0.006). In particular, a significantly higher incidence of ONJ was observed among patients treated with ZA alone (9.1 per 100 person-years) than among those treated with pamidronate þ ZA (1.6 per 100 person-years). Five cases of ONJ occurred at a median time of 9 months after the start of the study, namely 21 months from the first dose (IQR 7-12) in the group treated only with ZA, while two cases occurred at a median time of 43 months after the start of the study (IQR 34-51) in the pamidronate þ ZA treatment group. No cases of ONJ were Reduced risk of ONJ with a different schedule of zoledronic acid A Corso et al observed in group treated only with pamidronate. The overall median duration of treatment with each drug/combination was 23 months (IQR 15-39) for the pamidronate group, 28 (21-34) for the ZA group, and 47 months (25-58) for the pamidronate þ ZA group (Po0.000).
Discussion
In this single-center study we report the results of an analysis of the incidence of ONJ in a cohort of MM patients treated with bisphosphonates according to two different schedules: standard (monthly administrations) or reduced (monthly administrations for the first year then every 3 months). Even though this is a retrospective analysis, the two groups were comparable for various characteristics, including the extent of bone disease, concomitant therapy and disease status. To reduce further the possibility of bias, the differences observed between the two groups were adjusted for by the propensity score to exclude the possibility that the group of patients treated with the standard schedule of bisphosphonates could have included those with a worse clinical condition.
The main finding of our study was that the incidence of ONJ was lower in patients treated with the reduced schedule than with the standard schedule of bisphosphonate administration, started after the first year of treatment. At the same time the incidence of SRE was comparable in the two groups. The overall incidence of ONJ in our study was 3.2 per 100 person-years, and it was 6.7 per 100 person-years in patients treated with the standard schedule, in line with other published incidences. In a web-based survey, performed by the International Myeloma Foundation, of both breast cancer and MM patients, Durie et al. 10 reported that the incidence of ONJ ranged between 4.4 and 6.8%, respectively. In this study ONJ was observed significantly more frequently with ZA than with pamidronate. In another retrospective study of 90 MM patients, ONJ was reported in 3% of patients. 12 Bamias et al. 11 reviewed 252 patients with cancer, including 100 with MM, who received at least six infusions of bisphosphonate and reported that the incidence of ONJ was 9.9% among the MM patients. None of the patients treated with pamidronate alone experienced this complication. Similarly, in our study we observed a higher incidence of ONJ in patients treated with ZA with respect to those receiving pamidronate alone or pamidronate and ZA sequentially. The difference between patients treated with pamidronate or with ZA did not reach statistical significance probably owing to the small number of patients treated only with pamidronate. In contrast, the difference was significant between those treated with ZA alone and those treated with ZA þ pamidronate. The occurrence of ONJ was markedly delayed in the latter (9 months versus 43 months) and the incidence rate was almost 6 times lower (9.1 versus 1.6 100 person-years). Since these patients were treated first with pamidronate and then with ZA, these results could be further indirect confirmation of the low risk of developing ONJ during pamidronate therapy.
In our study we observed a statistically significant, eight-fold lower risk of developing ONJ in patients treated with a reduced schedule of bisphosphonates with respect to the standard schedule (adjusted HR ¼ 0.12, 95% CI 0.01-0.99, P ¼ 0.049). Furthermore, the single case of ONJ in patients treated with a reduced schedule was observed after a longer period of exposure. As reported in the literature, 1, 11, 12 all the patients who developed ONJ had a previous history of dental procedures. Our observation that the majority of cases of ONJ occurred relatively early, during the second year of treatment, is not in accordance with the data in the literature. Other studies, in fact, report duration of exposure and the number of infusions as major risk factors, 1, 11, 12 with a longer median exposure to the drug and a higher number of infusions in patients developing ONJ.
The emergence of ONJ as a serious long-term complication has deeply changed the approach to the use of bisphosphonates in MM leading to the definition of new guidelines.
14 In particular, the authors recommend to discontinue bisphosphonates after 2 years in patients achieving complete response or plateau phase. For patients still requiring treatment beyond 2 years, it is recommended to administer bisphosphonates every 3 months. Our study is the first that provides an evidence-based rationale for the application of this alternative schedule.
In conclusion, although pamidronate seems to be associated with a lower risk of developing ONJ there are some advantages in using ZA for the treatment of bone disease in MM patients. Therefore, a reduced schedule of administration of ZA could represent a possible solution to lower significantly the risk of ONJ while maintaining the efficacy of the bisphosphonate.
